Tell us how we can help
Clinician-to-clinician guidance
Coding, billing and reimbursement questions
Finding my sales representative
Support with an order
More than 20 clinical studies with more than 5,000 premature infants have demonstrated the effectiveness of Prolacta’s 100% human milk–based nutritional products.1
Our products, as part of an exclusive human milk diet (EHMD), have been shown in clinical studies to:
Prolacta’s human milk–based nutritional products contain a wide range of human milk oligosaccharides (HMOs), special sugars abundantly found in human milk.9 HMOs promote the development and maturation of the newborn immune system and provide a supplementary source of sialic acid critical for brain development. 10,11
Prolacta’s Humavant+ fortifier is the first commercially available human milk fortifier made from 100% human milk.
Human milk caloric fortifier is ideal for neonatal infants receiving low caloric content. Data show that 65% of the time, term mother’s own milk (MOM) is less than 20 Cal/fl oz.12 Humavant CR human milk caloric fortifier can meet the need for additional calories.
Humavant CR human milk caloric fortifier is the only completely human solution created to add calories to mother’s own milk (MOM) or donor breastmilk (DM) without substantially increasing volume and without introducing a non-human milk-based nutritional product.
A randomised clinical trial found that premature infants who received an exclusive human milk diet (EHMD) with Humavant CR fortifier had superior length and weight velocity compared to infants who received an exclusive human milk diet (EHMD) without Humavant CR fortifier.13
This study is a subset analysis of data originally published in 2014 by Hair et al in The Journal of Pediatrics.
Clinical Studies and Publications:
Humavant® RTF (Ready-To-Feed) offers Special Care Baby Units (NICU)s superior solutions for their extremely premature infants when mother’s own milk is not available.
Human Milk-Based Premature Infant Formula
Prolacta’s products, when used as part of an exclusive human milk diet (EHMD), have been shown to reduce the incidence of clinical complications.
In a multicentre, retrospective cohort study with 1587 patients, the outcomes of extremely premature infants (<1250 g birth weight) who received a diet including cow milk–based products were compared with infants who received an Exclusive Human Milk Diet (EHMD). The incidence of mortality, necrotising enterocolitis (NEC), bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), and late-onset sepsis were all reduced with an Exclusive Human Milk Diet (EHMD).13
Very low birth weight babies are at risk for prematurity-related morbidities and interventions, such as bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), late-onset sepsis, and necrotising enterocolitis (NEC). The incremental cost of these morbidities and interventions can substantially increase the cost of Special Care Baby Unit (NICU) hospitalisation.
Clinician-to-clinician guidance
Coding, billing and reimbursement questions
Finding my sales representative
Support with an order